NCT03314922 - A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

May 5, 2020

Study Completion Date

March 9, 2023

Conditions

Lymphoma

Interventions

DRUG

Parsaclisib

Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.

Trial Locations (6)

Aichi Cancer Center Hospital, Aichi

National Hospital Organization Kyushu Cancer Center, Fukuoka

Cancer Institute Hospital of Jfcr, Kōtoku

Nagoya City University Hospital, Nagoya

Tohoku University Hospital, Sendai

National Cancer Center Hospital, Tokyo